Cargando…

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

SIMPLE SUMMARY: Antibody–drug conjugates (ADC) have shown remarkable therapeutic activity in a wide range of hematologic and solid tumors. Herein, we discuss the mechanisms of action of ADCs, the desirable “bystander killing”, and the limitations associated with the design of each drug. We will also...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gogia, Pooja, Ashraf, Hamza, Bhasin, Sidharth, Xu, Yiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417123/ https://www.ncbi.nlm.nih.gov/pubmed/37568702 http://dx.doi.org/10.3390/cancers15153886

Ejemplares similares

Exploring Data and Literature Currently Available on the COVID-19 Vaccines
por: Gogia, Pooja, et al.
Publicado: (2022)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022)

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
por: Esapa, Benjamina, et al.
Publicado: (2023)

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
por: Liao, Michael Z., et al.
Publicado: (2021)

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
por: Barreca, Marilia, et al.
Publicado: (2022)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
por: McNamara, Blair, et al.
Publicado: (2023)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Exploration of the antibody–drug conjugate clinical landscape
por: Maecker, Heather, et al.
Publicado: (2023)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Rapidly Progressing Primary Membranous Nephropathy in a Hispanic Male With Elevated Levels of Anti-phospholipase A2 Receptor Antibodies
por: Ashraf, Hamza, et al.
Publicado: (2021)

Antibody–Drug Conjugates—A Tutorial Review
por: Baah, Stephanie, et al.
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives
por: Sganga, Stefano, et al.
Publicado: (2023)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Recent advances of antibody drug conjugates for clinical applications
por: Zhao, Pengxuan, et al.
Publicado: (2020)

Perioperative sildenafil therapy for children with ventricular septal defects and associated pulmonary hypertension undergoing corrective surgery: A randomised clinical trial
por: Bhasin, Sidharth, et al.
Publicado: (2017)

Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein
por: Gogia, Pooja, et al.
Publicado: (2022)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Mechanisms of Resistance to Antibody-Drug Conjugates
por: Khoury, Rita, et al.
Publicado: (2023)

The use of mechanistic evidence in drug approval
por: Aronson, Jeffrey K., et al.
Publicado: (2018)

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
por: Dan, Nirnoy, et al.
Publicado: (2018)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
por: Hammood, Manar, et al.
Publicado: (2021)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Thrombotic Thrombocytopenic Purpura: Revisiting a Miss and an Inevitable Consequence
por: Gogia, Pooja, et al.
Publicado: (2020)

Silver Nanoparticle Conjugation-Enhanced Antibacterial Efficacy of Clinically Approved Drugs Cephradine and Vildagliptin
por: Masri, Abdulkader, et al.
Publicado: (2018)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gfm3bechmvv0lh0re06m560s3j